AI assistant
Sending…
Terns Pharmaceuticals, Inc. — Director's Dealing 2024
Jul 3, 2024
32559_dirs_2024-07-02_404cf9ab-7690-4e8c-ac01-8accae5f3900.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2024-07-01
Reporting Person: FELLOWS DAVID A (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-07-01 | Stock Option (Right to Buy) | $6.85 | A | 8183.00 | Acquired | 2034-06-30 | Common Stock (8183.00) | Direct |
Footnotes
F1: This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $35,000 for the third and fourth quarters of 2024.
F2: The option will vest as to 1/6th of the total shares subject thereto on each monthly anniversary of the date of grant, such that 100% of the shares subject to the option will be fully vested on January 1, 2025.